Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Herr

Showing results (51-60 of 144) with videos related to

Pageof 15
Sort By:
Progress in Clinical and Biological Research|January 1, 1986
Surgical techniques in the management of patients with superficial bladder cancerM S Soloway, K H Kurth, H Herr, et al.
Marine Environmental Research|July 25, 2017
Marine debris in harbour porpoises and seals from German watersB Unger, H Herr, H Benke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancerG Dalbagni, W Han, Z F Zhang, et al.
British Journal of Urology|March 1, 1997
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II studyM S Cookson, P C Sogani, P Russo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Cancer|January 15, 1992
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better toleratedR J Motzer, S C Gulati, J P Crown, et al.
Science Robotics|November 7, 2020
On prosthetic control: A regenerative agonist-antagonist myoneural interfaceS S Srinivasan, M J Carty, P W Calvaresi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Cancer|December 15, 1990
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Pageof 15

Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
Progress in Clinical and Biological Research|January 1, 1986
Surgical techniques in the management of patients with superficial bladder cancerM S Soloway, K H Kurth, H Herr, et al.
Marine Environmental Research|July 25, 2017
Marine debris in harbour porpoises and seals from German watersB Unger, H Herr, H Benke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancerG Dalbagni, W Han, Z F Zhang, et al.
British Journal of Urology|March 1, 1997
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II studyM S Cookson, P C Sogani, P Russo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Cancer|January 15, 1992
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better toleratedR J Motzer, S C Gulati, J P Crown, et al.
Science Robotics|November 7, 2020
On prosthetic control: A regenerative agonist-antagonist myoneural interfaceS S Srinivasan, M J Carty, P W Calvaresi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Cancer|December 15, 1990
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Pageof 15